Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
18 hedge funds and large institutions have $2.22M invested in Iterum Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
350% more capital invested
Capital invested by funds: $495K → $2.22M (+$1.73M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
20% more funds holding
Funds holding: 15 → 18 (+3)
6.38% more ownership
Funds ownership: 2.61% → 8.99% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.59M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$295K |
| 3 |
AGM
Alpine Global Management
New York
|
+$77.1K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$39.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$73.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.43K |
| 4 |
KFS
Kelly Financial Services
Braintree,
Massachusetts
|
-$137 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$114 |
ITRM Hedge Fund Activity: Q3 2024 in Review
18 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q3 2024, worth a combined $2.22M — up 350% from $495K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ITRM positions and 5 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.59M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $73.3K sold.
- 18 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2024, up from 15 in Q2 2024.
- Funds reported $2.22M of Iterum Therapeutics stock for Q3 2024, up 350% quarter-over-quarter.
- 8 funds opened new Iterum Therapeutics positions in Q3 2024 and 5 closed out, a net change of +3 holders.
- The largest Iterum Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $1.59M added.
- The largest Iterum Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $73.3K sold.
Based on aggregated 13F filings for Q3 2024.